Triple-negative breast carcinoma: Current and emerging concepts

Robert Schmadeka, Bryan E. Harmon, Meenakshi Singh

Research output: Contribution to journalReview article

81 Citations (Scopus)

Abstract

Objectives: Triple-negative breast cancer is regarded as an aggressive disease that affects a young patient population and for which effective targeted therapy is not yet available. Methods: Intense efforts have been made to gain a better understanding of this heterogeneous group of tumors from the histologic to the genomic and molecular levels. Results: Progress has been made, including the ability to subtype these tumors and the discovery of biomarkers toward which current therapeutic efforts are focused. Many novel targets under exploration have the potential to affect the clinical course of this disease. Conclusions This article reviews the current concepts regarding the clinicopathologic features of triple-negative breast carcinoma, its histologic subtypes, molecular classification, the prognostic and therapeutic potential of biomarkers, and emerging targeted therapies.

Original languageEnglish (US)
Pages (from-to)462-477
Number of pages16
JournalAmerican Journal of Clinical Pathology
Volume141
Issue number4
DOIs
StatePublished - 2014
Externally publishedYes

Fingerprint

Breast Neoplasms
Triple Negative Breast Neoplasms
Therapeutics
Tumor Biomarkers
Biomarkers
Population
Neoplasms

Keywords

  • Biomarkers
  • Breast cancer
  • Pathology
  • Therapeutic efforts
  • Triple negative

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Triple-negative breast carcinoma : Current and emerging concepts. / Schmadeka, Robert; Harmon, Bryan E.; Singh, Meenakshi.

In: American Journal of Clinical Pathology, Vol. 141, No. 4, 2014, p. 462-477.

Research output: Contribution to journalReview article

Schmadeka, Robert ; Harmon, Bryan E. ; Singh, Meenakshi. / Triple-negative breast carcinoma : Current and emerging concepts. In: American Journal of Clinical Pathology. 2014 ; Vol. 141, No. 4. pp. 462-477.
@article{904c1a6211a94b94b5c8727b8ed0be7b,
title = "Triple-negative breast carcinoma: Current and emerging concepts",
abstract = "Objectives: Triple-negative breast cancer is regarded as an aggressive disease that affects a young patient population and for which effective targeted therapy is not yet available. Methods: Intense efforts have been made to gain a better understanding of this heterogeneous group of tumors from the histologic to the genomic and molecular levels. Results: Progress has been made, including the ability to subtype these tumors and the discovery of biomarkers toward which current therapeutic efforts are focused. Many novel targets under exploration have the potential to affect the clinical course of this disease. Conclusions This article reviews the current concepts regarding the clinicopathologic features of triple-negative breast carcinoma, its histologic subtypes, molecular classification, the prognostic and therapeutic potential of biomarkers, and emerging targeted therapies.",
keywords = "Biomarkers, Breast cancer, Pathology, Therapeutic efforts, Triple negative",
author = "Robert Schmadeka and Harmon, {Bryan E.} and Meenakshi Singh",
year = "2014",
doi = "10.1309/AJCPQN8GZ8SILKGN",
language = "English (US)",
volume = "141",
pages = "462--477",
journal = "American Journal of Clinical Pathology",
issn = "0002-9173",
publisher = "American Society of Clinical Pathologists",
number = "4",

}

TY - JOUR

T1 - Triple-negative breast carcinoma

T2 - Current and emerging concepts

AU - Schmadeka, Robert

AU - Harmon, Bryan E.

AU - Singh, Meenakshi

PY - 2014

Y1 - 2014

N2 - Objectives: Triple-negative breast cancer is regarded as an aggressive disease that affects a young patient population and for which effective targeted therapy is not yet available. Methods: Intense efforts have been made to gain a better understanding of this heterogeneous group of tumors from the histologic to the genomic and molecular levels. Results: Progress has been made, including the ability to subtype these tumors and the discovery of biomarkers toward which current therapeutic efforts are focused. Many novel targets under exploration have the potential to affect the clinical course of this disease. Conclusions This article reviews the current concepts regarding the clinicopathologic features of triple-negative breast carcinoma, its histologic subtypes, molecular classification, the prognostic and therapeutic potential of biomarkers, and emerging targeted therapies.

AB - Objectives: Triple-negative breast cancer is regarded as an aggressive disease that affects a young patient population and for which effective targeted therapy is not yet available. Methods: Intense efforts have been made to gain a better understanding of this heterogeneous group of tumors from the histologic to the genomic and molecular levels. Results: Progress has been made, including the ability to subtype these tumors and the discovery of biomarkers toward which current therapeutic efforts are focused. Many novel targets under exploration have the potential to affect the clinical course of this disease. Conclusions This article reviews the current concepts regarding the clinicopathologic features of triple-negative breast carcinoma, its histologic subtypes, molecular classification, the prognostic and therapeutic potential of biomarkers, and emerging targeted therapies.

KW - Biomarkers

KW - Breast cancer

KW - Pathology

KW - Therapeutic efforts

KW - Triple negative

UR - http://www.scopus.com/inward/record.url?scp=84899471315&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899471315&partnerID=8YFLogxK

U2 - 10.1309/AJCPQN8GZ8SILKGN

DO - 10.1309/AJCPQN8GZ8SILKGN

M3 - Review article

C2 - 24619745

AN - SCOPUS:84899471315

VL - 141

SP - 462

EP - 477

JO - American Journal of Clinical Pathology

JF - American Journal of Clinical Pathology

SN - 0002-9173

IS - 4

ER -